Abstract
Barnes KN, Pearce EF, Yancy AM, et al. Ospemifene in the treatment of vulvovaginal atrophy. Ann Pharmacother. 2014;48:752-757. (Original doi: 10.1177/1060028014526036 ) In the above article published in the June 2014 issue of Annals of Pharmacotherapy, it was stated that patients with a uterus taking ospemifene still need to use a progestogen to reduce the risk of hyperplasia. This is, in fact, unknown. Although patients with an intact uterus taking an agent with estrogenic properties are recommended to add a progestin to prevent hyperplasia, studies involving ospemifene alone found no increase in the risk of hyperplasia. There are currently no studies available evaluating the combination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
